Medica Scientia Innovation Research
Medica Scientia Innovation Research is recorded as a service provider in 3 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 3 of 3 trials · Latest update first
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/or clinically high-risk ER+/HER2- early breast cancer (ADAPTela)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)
Sponsor WSG Women's Cancer Study Group GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer
Sponsor Queen Mary University Of London
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Medica Scientia Innovation Research?
The 2026-10-09 snapshot links Medica Scientia Innovation Research to 3 distinct CTIS trials. Recorded services include Project management, Regulatory services, Clinical monitoring, Investigator recruitment. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Medica Scientia Innovation Research?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Medica Scientia Innovation Research conducted?
The linked trials record locations in 4 countries, including Germany, Spain, Austria, Poland. These are trial locations, not confirmed office locations or countries where Medica Scientia Innovation Research delivered services.
What can this page tell me about Medica Scientia Innovation Research's trial experience?
Browse 3 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Medica Scientia Innovation Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Medica Scientia Innovation Research S.L.
- Medica Scientia Innovation Research SL